KRAS and neoplasm: Conflicting findings have been reported, particularly in KRAS G12D‐driven NSCLC.[47] In this subtype, PD‐L1 expression was lower in both tumor cells and immune cells compared to non‐G12D‐driven KRAS NSCLC.